Clinical Trials Directory

Trials / Completed

CompletedNCT01689181

Apathy in Schizophrenia

L'apathie Dans La Schizophrénie: Étude Neuropsychologique Et Anatomique

Status
Completed
Phase
Study type
Observational
Enrollment
60 (actual)
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France · Other Government
Sex
All
Age
20 Years – 55 Years
Healthy volunteers
Accepted

Summary

Apathy, defined as a quantitative reduction of voluntary, goal-directed behaviours (GDB), is a core component of negative symptoms. It has been suggested that the physiopathology of apathy is not a single entity but may be multiple, depending on which specific process or macrofunction is disrupted during completion of GDB. In line with this notion, Levy and Dubois proposed dividing apathic syndromes into three subtypes of disrupted processing: 'a-motivation', 'cognitive inertia', and 'uncoupling'. In schizophrenia, apathy has been associated with executive dysfunction, functional impairment and poor outcome. However, the neurobiological underpinnings of apathy in schizophrenia are poorly understood. Primary objective: confirm that chronic schizophrenic patients are apathic compared to healthy volunteers Secondary objectives: * investigate if apathy is related to a particular aspect of the disease (i.e. negative, positive symptomatology and/or deficit form) * investigate if apathy correlates with executive dysfunction * investigate if apathy is associated with a specific mechanism using an experimental task specially designed to investigate the different mechanism (i.e. 'a-motivation', 'cognitive inertia', and 'uncoupling') * investigate if there is a volumetric abnormality affecting the executive system in apathic schizophrenic patients * link these eventual volumetric abnormalities to prefrontal cortex-basal ganglia circuits according to a specific subtype of apathy in the apathic schizophrenic group

Conditions

Timeline

Start date
2012-06-01
Primary completion
2013-06-05
Completion
2013-06-05
First posted
2012-09-21
Last updated
2025-01-23

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01689181. Inclusion in this directory is not an endorsement.